New pill for chronic hives tested in Real-World patient survey
NCT ID NCT07408219
First seen Feb 19, 2026 · Last updated May 17, 2026 · Updated 14 times
Summary
This study tracks 350 adults with chronic spontaneous urticaria (long-lasting hives) who are starting a new medication called remibrutinib. Researchers will use patient questionnaires to measure how well the drug controls symptoms like itching and swelling over the first month. The goal is to see if remibrutinib works effectively in real-world settings, not just in controlled clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis
RECRUITINGEast Hanover, New Jersey, 07936, United States
Conditions
Explore the condition pages connected to this study.